GBEX Updating Website to be Integrated with Office Depot
During the GBEX web
integration transition with Office Depot, please do not place orders between Dec. 28, 2016 and Jan. 2, 2017.
What will change?
-
Your username and password.
Your username will be changed to your UC email address. Over the winter season days, an email with your temporary password and a guide on how to take full advantage of the updated website will be sent to you via email.
What will remain the same?
- GBEX web address: gbexllc.com
- Customer service team and sales representatives: CustomerService@GBEXLLC.com / 855-372-4239
- Deliveries by the same drivers.
Please note that you will continue to receive the same high level of support received from GBEX and Central Stores customer service, deliveries, and sales teams. None of the payment processes will change, and overall, the process for placing your office supply orders will be improved!
If you have any specific questions on the web transition and its impact to you and the university, please contact UC Central Stores at
or 513-556-5659.
Thank you for your cooperation during our transition, and Central Stores looks forward to continuing our partnership with GBEX for years to come.
265 Tangeman University Center
University of Cincinnati
Cincinnati, OH 45221-0217
513-556-5659
Related Stories
Get to know CCM’s newest faculty and staff members
September 2, 2026
UC’s College-Conservatory of Music will welcome a variety of new faculty and staff members to its roster of distinguished performing and media arts experts, researchers and educators this fall.
How two UC co-ops joined Procter & Gamble for fast-track innovation
September 2, 2026
University of Cincinnati cooperative learning students observed a real-world creative workshop with Procter & Gamble on an early-stage product.
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.